Navigation

Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib [ID362]

Dasatinib, nilotinib and standard-dose imatinib within their licensed indications for the first-line treatment of chronic myeloid leukaemia (including part-review of TA70)

Status: History
Expected date of issue: April 2012
Referral date: July 2010
Process: MTA
Topic area:
  • Cancer
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Matthew Dyer
Communications manager: Alice Law
Project manager: Lori Farrar
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 25 May 2011
1st appraisal committee meeting: 08 November 2011
2nd appraisal committee meeting: 08 February 2012
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Bristol-Myers Squibb (dasatinib)
  • Novartis Pharmaceuticals (imatinib, nilotinib)

Patient/carer groups

  • African Caribbean Leukaemia Trust
  • Chronic Myeloid Leukaemia Support Group
  • Leukaemia CARE
  • Macmillan Cancer Support
  • The Hepatitis B Foundation UK

Professional groups

  • British Society for Haematology
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • NHS North Yorkshire and York
  • Welsh Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturers

  • None

Relevant research groups

  • Leukaemia & Lymphoma Research

Evidence Review Group

  • Peninsula Technology Assessment Group, University of Exeter (PenTAG)
  • National Coordinating Centre for Health Technology Assessment

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
6 August 2010 Nilotinib for the first line treatment of chronic myeloid leukaemia was referred to NICE as a Single Technology Appraisal (STA). 

NICE have recently undertaken a draft scope consultation exercise and held a scoping workshop for the proposed appraisal of dasatinib for the first line treatment of chronic myeloid leukaemia. 

As a result of this work, the Department of Health has now asked NICE  to carry out a multiple technology appraisal of dasatinib, nilotinib and standard-dose imatinib within their licensed indications for the first-line treatment of chronic myeloid leukaemia (including part-review of TA70) as part of our 24th wave work programme. 

Therefore nilotinib will not be appraised through the STA process.
Top


 

Key documents

This page was last updated: 11 June 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.